Mothaffar F Rimawi

List of Publications by Year
in descending order

136 papers	7,000 citations	61857 43 h-index	60497 81 g-index
139 all docs	139 docs citations	139 times ranked	10101 citing authors

#	Article	IF	Citations
1	Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER+/HER2â^' Breast Cancer. Clinical Cancer Research, 2022, 28, 163-174.	3.2	8
2	Abstract P5-14-02: Breast cancer clinical trial participation rate among patients of low socioeconomic status at a comprehensive cancer center. Cancer Research, 2022, 82, P5-14-02-P5-14-02.	0.4	0
3	Abstract OT2-11-09: Lidera breast cancer: A phase III adjuvant study of giredestrant (GDC-9545) vs physicianâ€™s choice of endocrine therapy (ET) in patients (pts) with estrogen receptor-positive, HER2-negative early breast cancer (ER+/HER2- EBC). Cancer Research, 2022, 82, OT2-11-09-OT2-11-09.	0.4	5
4	Abstract OT1-14-02: Phase 3 study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line (1L), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09. Cancer Research, 2022, 82, OT1-14-02-OT1-14-02.	0.4	1
5	Abstract PD4-02: Safety and efficacy of a tucatinib-trastuzumab-capecitabine regimen for treatment of leptomeningeal metastasis (LM) in HER2-positive breast cancer: Results from TBCRC049, a phase 2 non-randomized study. Cancer Research, 2022, 82, PD4-02-PD4-02.	0.4	12
6	Abstract PD2-07: Impact of using cross-platform gene expression profiling technologies and computational methods for intrinsic breast cancer subtyping in PALOMA-2 and PALLET. Cancer Research, 2022, 82, PD2-07-PD2-07.	0.4	0
7	Abstract PD1-05: Targeting the FRA1-dependent transcriptional nexus in high FOXA1-driven endocrine-resistant and metastatic breast cancer. Cancer Research, 2022, 82, PD1-05-PD1-05.	0.4	0
8	Abstract PD8-06: Acquired resistance to tucatinib is associated with EGFR amplification in HER2+ breast cancer (BC) models and can be overcome by a more complete blockade of HER receptor layer. Cancer Research, 2022, 82, PD8-06-PD8-06.	0.4	1
9	Abstract OT1-18-07: A randomized, multicenter, placebo-controlled, phase III study to evaluate the efficacy and safety of HER2/neu peptide GLSI-100 (GP2 + GM-CSF) in patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy. Cancer Research, 2022, 82, OT1-18-07-OT1-18-07.	0.4	0
10	Abstract PD15-03: Overlapping molecular features (proliferation, immune signatures) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 387 Td (and Cancer Research, 2022, 82, PD15-03-PD15-03.	0.4	0
11	Abstract P5-07-01: Proteogenomic analysis of differential chemotherapy responses in patient-derived xenografts of triple-negative breast cancer. Cancer Research, 2022, 82, P5-07-01-P5-07-01.	0.4	0
12	Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. Npj Breast Cancer, 2022, 8, 18.	2.3	8
13	Abstract P4-01-01: Resistance to next generation tyrosine kinase inhibitors (TKIs) in HER2-positive breast cancer (BC): Role of HER and PIK3CA mutations and development of new treatment strategies and study models. Cancer Research, 2022, 82, P4-01-01-P4-01-01.	0.4	1
14	Abstract P2-09-09: Genetic assessment of hereditary breast and ovarian cancer in the Smith Clinic: A 10-year, single center experience. Cancer Research, 2022, 82, P2-09-09-P2-09-09.	0.4	0
15	Abstract CT232: A randomized, multicenter, placebo-controlled, phase III study to evaluate the efficacy and safety of HER2/neu peptide GLSI-100 (GP2 + GM-CSF) in patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, Flamingo-01. Cancer Research, 2022, 82, CT232-CT232.	0.4	0
16	Elacestrant and the Promise of Oral SERDs. Journal of Clinical Oncology, 2022, 40, 3227-3229.	0.8	10
17	Effect of mevalonate pathway inhibitors on outcomes of patients (pts) with HER2-positive early breast cancer (BC) in the ALTTO trial.. Journal of Clinical Oncology, 2022, 40, 522-522.	0.8	0
18	A randomized, multicenter, placebo-controlled, phase III study to evaluate the efficacy and safety of HER2/neu peptide GLSI-100 (GP2 + GM-CSF) in patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, Flamingo-01.. Journal of Clinical Oncology, 2022, 40, TPS1110-TPS1110.	0.8	1

#	Article	IF	Citations
19	Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211071.	1.4	6
20	Abstract PD3-09:HER2 L755Smutation is acquired upon resistance to lapatinib and neratinib and confers cross-resistance to tucatinib and trastuzumab in HER2-positive breast cancer cell models. , 2021, , .		2
21	Abstract PS5-29: Insights into the molecular underpinnings of the mevalonate pathway-YAP/TAZ-driven anti-HER2 therapy resistance in HER2+ breast cancer (BC). , 2021, , .		0
22	Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. Clinical Cancer Research, 2021, 27, 4870-4882.	3.2	49
23	Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. Cancers, 2021, 13, 1458.	1.7	17
24	Abstract P33: Disparities in breast cancer screening and the impact of COVID-19 in Houston, Texas. , 2021, , .		0
25	A phase 1/2 trial of ORIN1001, a first-in-class IRE1 inhibitor, in patients with advanced solid tumors.. Journal of Clinical Oncology, 2021, 39, 3080-3080.	0.8	10
26	Genetic assessment of hereditary breast and ovarian cancer in the Harris Health System: A five-year, single-center experience.. Journal of Clinical Oncology, 2021, 39, 10587-10587.	0.8	0
27	Change in management based on actionable mutations in metastatic breast cancer in an ethnically diverse cohort: Single institution experience.. Journal of Clinical Oncology, 2021, 39, e13067-e13067.	0.8	0
28	Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models. Npj Breast Cancer, 2021, 7, 63.	2.3	4
29	A prospective, randomized, multicenter, double-blinded, placebo-controlled phase III trial of the HER2/neu peptide GP2 + GM-CSF versus bacteriostatic saline/WFI placebo as adjuvant therapy after any trastuzumab-based therapy in HER2-positive women with operable breast cancer.. Journal of Clinical Oncology, 2021, 39, TPS604-TPS604.	0.8	0
30	ImmunogenomicÂprofiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer. Breast Cancer Research and Treatment, 2021, 189, 187-202.	1.1	24
31	Lumpectomy followed by radiation improves survival in HER2 positive and tripleâ€negative breast cancer with high tumorâ€infiltrating lymphocytes compared to mastectomy alone. Cancer Medicine, 2021, 10, 4790-4795.	1.3	6
32	Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). Breast Cancer Research and Treatment, 2021, 189, 103-110.	1.1	19
33	Abstract CT256: A prospective, randomized, multicenter, double-blinded, placebo-controlled phase III trial of the HER2/neu peptide GP2 + GM-CSF versus bacteriostatic saline/WFI placebo as adjuvant therapy after any trastuzumab-based therapy in HER2-positive women with operable breast cancer. , 2021, , .		0
34	Abstract 2992: Proteogenomic characterization of triple-negative breast cancer patient-derived xenografts reveals molecular correlates of differential chemotherapy response and potential therapeutic targets to overcome resistance. , 2021, , .		0
35	Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. Journal of Clinical Oncology, 2021, 39, 2247-2256.	0.8	22
36	Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. Journal of Clinical Oncology, 2021, 39, 2375-2385.	0.8	76

#	Article	IF	Citations
37	Management of hormone receptorâ€“positive, human epidermal growth factor 2â€“negative metastatic breast cancer. Breast Cancer Research and Treatment, 2021, 190, 189-201.	1.1	10
38	HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. Journal of the National Cancer Institute, 2020, 112, 46-54.	3.0	97
39	Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. Clinical Breast Cancer, 2020, 20, 145-151.e2.	1.1	21
40	Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy. Clinical Cancer Research, 2020, 26, 738-745.	3.2	31
41	Towards personalized treatment for early stage HER2-positive breast cancer. Nature Reviews Clinical Oncology, 2020, 17, 233-250.	12.5	166
42	TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer. Clinical Cancer Research, 2020, 26, 821-827.	3.2	40
43	Dose-reduced trastuzumab deruxtecan can be safely used in liver failure and active leptomeningeal metastases. Current Problems in Cancer Case Reports, 2020, 2, 100034.	0.1	1
44	HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. Cancer Treatment Reviews, 2020, 84, 101965.	3.4	92
45	Microscaled proteogenomic methods for precision oncology. Nature Communications, 2020, 11, 532.	5.8	78
46	A multiparameter classifier to predict response to lapatinib plus trastuzumab (LT) without chemotherapy in HER2+ breast cancer (BC).. Journal of Clinical Oncology, 2020, 38, 1011-1011.	0.8	4
47	A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer. Journal of Clinical Medicine, 2019, 8, 1772.	1.0	36
48	Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer. Molecular Cancer Research, 2019, 17, 2318-2330.	1.5	41
49	Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia. Breast Cancer Research and Treatment, 2019, 177, 427-435.	1.1	11
50	TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. Journal of Clinical Oncology, 2019, 37, 714-722.	0.8	36
51	Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis. BMC Cancer, 2019, 19, 220.	1.1	19
52	Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptorâ€“Positive Early Breast Cancer: PALLET Trial. Journal of Clinical Oncology, 2019, 37, 178-189.	0.8	136
53	TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer and Brain Metastases. Journal of Clinical Oncology, 2019, 37, 1081-1089.	0.8	251
54	FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 26823-26834.	3.3	103

#	Article	IF	Citations
55	The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance. British Journal of Cancer, 2019, 120, 331-339.	2.9	48
56	TBCRC 030: A randomized phase II study of preoperative cisplatin versus paclitaxel in TNBCâ€"Evaluating the homologous recombination deficiency (HRD) biomarker.. Journal of Clinical Oncology, 2019, 37, 507-507.	0.8	9
57	Biomarker analysis of PALLET: A neoadjuvant trial of letrozole (L) Â± palbociclib (P).. Journal of Clinical Oncology, 2019, 37, 570-570.	0.8	9
58	Abstract 4064: Association of molecular signatures, mutations, and sTILs, with pCR in breast cancer patients in NRG Oncology/NSABP B-52. , 2019, , .		1
59	Abstract 4827: The therapeutic superiority of neratinib in combination with trastuzumab compared to pertuzumab plus trastuzumab in HER2-positivein vivobreast cancer models. , 2019, , .		0
60	Abstract 4757: Targeting the mevalonate pathway in HER2+breast cancer to overcome resistance and enhance anti-HER2 therapy efficacy. , 2019, , .		0
61	Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer. Nature Medicine, 2018, 24, 505-511.	15.2	47
62	Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Research and Treatment, 2018, 167, 731-740.	1.1	71
63	Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27. Clinical Breast Cancer, 2018, 18, 78-87.	1.1	13
64	First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2â€"Positive and Hormone Receptorâ€"Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial. Journal of Clinical Oncology, 2018, 36, 2826-2835.	0.8	152
65	Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. Journal of Clinical Oncology, 2018, 36, 1073-1079.	0.8	102
66	PAM50 HER2-enriched/ERBB2-high (HER2-E/ERBB2H) biomarker to predict response and survival following lapatinib (L) alone or in combination with trastuzumab (T) in HER2+ T-refractory metastatic breast cancer (BC): A correlative analysis of the EGF104900 phase III trial.. Journal of Clinical Oncology, 2018, 36, 1025-1025.	0.8	3
67	HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: A combined analysis of TBCRC006/023 and PAMELA trials.. Journal of Clinical Oncology, 2018, 36, 509-509.	0.8	10
68	TBCRC026: Phase II clinical trial assessing the correlation of standardized uptake value (SUV) on positron emission tomography (PET) with pathological complete response (pCR) to pertuzumab and trastuzumab in patients with primary operable HER2-positive breast cancer.. Journal of Clinical Oncology, 2018, 36, 511-511.	0.8	4
69	Palbociclib after CDK and endocrine therapy (PACE): A randomized phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+/HER2- metastatic breast cancer.. Journal of Clinical Oncology, 2018, 36, TPS1104-TPS1104.	0.8	13
70	Retrospective review of genomic testing in breast cancer: Does it improve outcome?. Breast Cancer Research and Treatment, 2017, 163, 191-195.	1.1	0
71	Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer. JAMA - Journal of the American Medical Association, 2017, 317, 596.	3.8	163
72	HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. Clinical Cancer Research, 2017, 23, 5123-5134.	3.2	85

#	Article	IF	Citations
73	De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. Breast, 2017, 34, S19-S26.	0.9	46
74	Scalp Cooling Alopecia Prevention trial (SCALP) for patients with early stage breast cancer.. Journal of Clinical Oncology, 2017, 35, 10088-10088.	0.8	2
75	Chemotherapy (CT) for isolated locoregional recurrence (ILRR) of breast cancer in ER-positive (ER+) and ER-negative (ER-) cohorts: Final analysis of the CALOR trial.. Journal of Clinical Oncology, 2017, 35, 513-513.	0.8	1
76	TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis. Clinical Cancer Research, 2016, 22, 5706-5712.	3.2	30
77	Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes. Cancer Research, 2016, 76, 6495-6506.	0.4	105
78	Metastatic human epidermal growth factor receptor 2-positive breast cancer: Management, challenges, and future directions. Current Problems in Cancer, 2016, 40, 117-129.	1.0	1
79	FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E6600-E6609.	3.3	119
80	Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer and Brain Metastases. Journal of Clinical Oncology, 2016, 34, 945-952.	0.8	148
81	Evaluation of tumor immune infiltrate as a determinant of response to neo-adjuvant lapatinib and trastuzumab (LT) in HER2-positive (+) breast cancer (BC).. Journal of Clinical Oncology, 2016, 34, 608-608.	0.8	1
82	Scalp cooling alopecia prevention trial (SCALP) for patients with early stage breast cancer.. Journal of Clinical Oncology, 2016, 34, TPS10144-TPS10144.	0.8	0
83	Vitamin D and aromatase inhibitor-induced arthralgia: Analysis of Canadian cancer trial group MA.27 data.. Journal of Clinical Oncology, 2016, 34, 10020-10020.	0.8	0
84	Resistance to Anti-HER2 Therapies in Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e157-e164.	1.8	24
85	A Neoadjuvant, Randomized, Open-Label Phase II Trial of Afatinib Versus Trastuzumab Versus Lapatinib in Patients With Locally Advanced HER2-Positive Breast Cancer. Clinical Breast Cancer, 2015, 15, 101-109.	1.1	40
86	Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy. Clinical Cancer Research, 2015, 21, 3995-4003.	3.2	82
87	Targeting HER2 for the Treatment of Breast Cancer. Annual Review of Medicine, 2015, 66, 111-128.	5.0	213
88	Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis. Breast Cancer Research, 2015, 17, 3.	2.2	48
89	Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). Journal of Clinical Oncology, 2015, 33, 2623-2631.	0.8	49
90	Effects of a green tea extract, Polyphenon E, on systemic biomarkers of growth factor signalling in women with hormone receptorâ€negative breast cancer. Journal of Human Nutrition and Dietetics, 2015, 28, 272-282.	1.3	45

#	Article	IF	Citations
91	Breast adenocarcinoma recurring as small cell carcinoma in a patient with a germline BRCA2 mutation: clonal evolution unchecked. Experimental Hematology and Oncology, 2015, 4, 1.	2.0	8
92	Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers. Clinical Cancer Research, 2015, 21, 1098-1105.	3.2	35
93	A Phase II Trial of Capecitabine Concomitantly With Whole-Brain Radiotherapy Followed by Capecitabine and Sunitinib for Brain Metastases From Breast Cancer. Oncologist, 2015, 20, 13-13.	1.9	11
94	Abstract PD3-5: Whole exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients with or without prior trastuzumab (T): A correlative analysis of TBCRC003. , 2015, , .		4
95	Abstract S6-02: TBCRC023: A randomized multicenter phase II neoadjuvant trial of lapatinib plus trastuzumab, with endcorine therapy and without chemotherapy, for 12 vs. 24 weeks in patients with HER2 overexpressing breast cancer. , 2015, , .		13
96	TBCRC-010: Phase I/II study of dasatinib in combination with zoledronic acid (ZA) for the treatment of breast cancer bone metastasis (MBC-bone).. Journal of Clinical Oncology, 2015, 33, 11080-11080.	0.8	1
97	Abstract P5-05-03: Clonal evolution of the HER2 L755S mutation leads to acquired HER-targeted therapy resistance that can be reversed by the irreversible HER1/2 inhibitor afatinib. , 2015, , .		0
98	Abstract P4-01-06: Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis. , 2015, , .		0
99	Abstract PD6-2: FoxA1 gene amplification in ER+ breast cancer mediates endocrine resistance by increasing IL-8. , 2015, , .		0
100	Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Research, 2014, 16, 430.	2.2	61
101	Aromatase Inhibitor Adverse Effects: Are We Sweeping Them Under the Rug?. Journal of Clinical Oncology, 2014, 32, 3779-3779.	0.8	8
102	Therapeutic potential of the dual EGFR/HER2Âinhibitor AZD8931 in circumventing endocrine resistance. Breast Cancer Research and Treatment, 2014, 144, 263-272.	1.1	49
103	Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. Lancet Oncology, The, 2014, 15, 156-163.	5.1	171
104	Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibodyâ€“drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates. Cancer Chemotherapy and Pharmacology, 2014, 74, 399-410.	1.1	69
105	Whole-exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients (pts) treated with prior trastuzumab (T): A correlative analysis of TBCRC003.. Journal of Clinical Oncology, 2014, 32, 536-536.	0.8	5
106	TBCRC030: A randomized, phase II study of preoperative cisplatin versus paclitaxel in patients (pts) with BRCA1/2-proficient triple-negative breast cancer (TNBC)â€”Evaluating the homologous recombination deficiency (HRD) biomarker.. Journal of Clinical Oncology, 2014, 32, TPS1145-TPS1145.	0.8	1
107	Scalp cooling alopecia prevention trial (SCALP).. Journal of Clinical Oncology, 2014, 32, TPS9660-TPS9660.	0.8	0
108	Abstract CT319: A randomized, controlled trial of high dose vs. standard dose vitamin D for aromatase inhibitor-induced arthralgia in breast cancer survivors. , 2014, , .		0

#	Article	IF	Citations
109	Development of Acneiform Rash Does Not Predict Response to Lapatinib Treatment in Patients with Breast Cancer. Pharmacotherapy, 2013, 33, 1126-1129.	1.2	5
110	Predictors of post-mastectomy reconstruction in an underserved population. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2013, 66, 763-769.	0.5	15
111	Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2â€“Overexpressing Breast Cancer: TBCRC 006. Journal of Clinical Oncology, 2013, 31, 1726-1731.	0.8	238
112	A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models. Cancer Research, 2013, 73, 4885-4897.	0.4	394
113	Phase IB Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women with Hormone Receptorâ€“Negative Breast Cancer. Cancer Prevention Research, 2012, 5, 1144-1154.	0.7	86
114	Challenges in the treatment of younger women with breast cancer. Breast Cancer Management, 2012, 1, 127-134.	0.2	0
115	TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2012, 30, 2615-2623.	0.8	413
116	Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. Breast Cancer Research and Treatment, 2012, 136, 795-804.	1.1	175
117	Making Sense of Clinical Trial Data: Is Inverse Probability of Censoring Weighted Analysis the Answer to Crossover Bias?. Journal of Clinical Oncology, 2012, 30, 453-458.	0.8	26
118	Blocking both driver and escape pathways improves outcomes. Nature Reviews Clinical Oncology, 2012, 9, 133-134.	12.5	11
119	Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies. Breast Cancer Research and Treatment, 2012, 134, 583-593.	1.1	31
120	Jejunal Intussusception Due to Malignant Phyllodes Tumor of the Breast. Clinical Breast Cancer, 2012, 12, 219-221.	1.1	6
121	A neoadjuvant, randomized, open-label phase II trial of afatinib (A) versus trastuzumab (T) versus lapatinib (L) in patients (pts) with locally advanced HER2-positive breast cancer (BC).. Journal of Clinical Oncology, 2012, 30, 606-606.	0.8	8
122	Pertuzumab in combination with trastuzumab plus an aromatase inhibitor in patients with hormone receptor-positive, HER2-positive metastatic breast cancer: A randomized phase II study (PERTAIN).. Journal of Clinical Oncology, 2012, 30, TPS654-TPS654.	0.8	4
123	Abstract LB-305: Circulating tumor cells as a novel model to test efficacy of individualized therapy in breast cancer. , 2012, , .		0
124	Î²1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib. Breast Cancer Research, 2011, 13, R84.	2.2	147
125	Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers - role of estrogen receptor and HER2 reactivation. Breast Cancer Research, 2011, 13, R121.	2.2	219
126	A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer. Breast Cancer Research and Treatment, 2011, 129, 819-827.	1.1	30

#	Article	IF	Citations
127	High IGF-IR Activity in Triple-Negative Breast Cancer Cell Lines and Tumorgrafts Correlates with Sensitivity to Antiâ€“IGF-IR Therapy. Clinical Cancer Research, 2011, 17, 2314-2327.	3.2	112
128	Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2â€“Overexpressing Locally Advanced Breast Cancers. Journal of Clinical Oncology, 2011, 29, 166-173.	0.8	235
129	Reduced Dose and Intermittent Treatment with Lapatinib and Trastuzumab for Potent Blockade of the HER Pathway in HER2/neu-Overexpressing Breast Tumor Xenografts. Clinical Cancer Research, 2011, 17, 1351-1361.	3.2	76
130	Self-blame, Self-forgiveness, and Spirituality in Breast Cancer Survivors in a Public Sector Setting. Journal of Cancer Education, 2010, 25, 343-348.	0.6	35
131	DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. Breast Cancer Research and Treatment, 2010, 123, 189-196.	1.1	65
132	Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer, 2010, 116, 1234-1242.	2.0	181
133	Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic Function. Cancer Research, 2008, 68, 826-833.	0.4	415
134	Treatment of Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer Xenografts With Multiagent HER-Targeted Therapy. Journal of the National Cancer Institute, 2007, 99, 694-705.	3.0	176
135	Mechanisms of Tumor Regression and Resistance to Estrogen Deprivation and Fulvestrant in a Model of Estrogen Receptorâ€“Positive, HER-2/neu-Positive Breast Cancer. Cancer Research, 2006, 66, 8266-8273.	0.4	147
136	Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemotherapy and Pharmacology, 2005, 56, 10-20.	1.1	170